We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Aprea Therapeutics Inc | NASDAQ:APRE | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.18 | -4.44% | 3.87 | 3.77 | 4.05 | 4.05 | 3.82 | 3.82 | 6,423 | 23:23:53 |
From Jul 2019 to Jul 2024
A live webcast of the presentation can be accessed from "Events Calendar" in the News and Events section of the Aprea website at Link.
About Aprea Therapeutics, Inc.
Aprea Therapeutics Inc., (NASDAQ: APRE) is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company’s lead product candidate is APR-246, a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).For more information, please visit the company website at www.aprea.com.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The forward-looking statements contained in this press release reflect Aprea’s current views with respect to future events, and Aprea does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Source: Aprea Therapeutics
Corporate Contacts:
Scott M. CoianteSr. Vice President and Chief Financial Officer617-463-9385
Gregory A. Korbel, Ph.D.Vice President of Business Development617-463-9385
1 Year Aprea Therapeutics Chart |
1 Month Aprea Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
